STING activation promotes autologous type I interferon–dependent development of type 1 regulatory T cells during malaria

Yulin Wang, … , Michelle J. Boyle, Christian R. Engwerda

*J Clin Invest.* 2023;133(19):e169417. [https://doi.org/10.1172/JCI169417](https://doi.org/10.1172/JCI169417).

**Graphical abstract**

Find the latest version:

[https://jci.me/169417/pdf](https://jci.me/169417/pdf)
STING activation promotes autologous type I interferon–dependent development of type 1 regulatory T cells during malaria

Yulin Wang,1,2 Fabian De Labastida Rivera,1 Chelsea L. Edwards,1,3 Teija C. M. Frame,1,3 Jessica A. Engel,1 Luzia Bukali,1,3 Jinrui Na,1,3 Susanna S. Ng,1,4 Dillon Corvino,1,4 Marcela Montes de Oca,5 Patrick T. Bunn,1 Megan S. F. Soon,1 Dean Andrew,1 Jessica R. Loughland,1 Jia Zhang,1 Fiona H. Amante,1 Bridget E. Barber,1 James S. McCarthy,6 J. Alejandro Lopez,1,2 Michelle J. Boyle,1,7 and Christian R. Engwerda1

1QIMR Berghofer Medical Research Institute, Brisbane, Australia. 2Griffith University, School of Environment and Science, Nathan, Australia. 3University of Queensland, School of Medicine, Brisbane, Australia. 4Institute of Experimental Oncology, University Hospital Bonn, Bonn, Germany. 5York Biomedical Research Institute, Hull York Medical School, University of York, York, United Kingdom. 6Victorian Infectious Diseases Services, Doherty Institute, University of Melbourne, Melbourne, Australia. 7Life Sciences Division, Burnet Institute, Melbourne, Australia.

The development of highly effective malaria vaccines and improvement of drug-treatment protocols to boost antiparasitic immunity are critical for malaria elimination. However, the rapid establishment of parasite-specific immune regulatory networks following exposure to malaria parasites hampers these efforts. Here, we identified stimulator of interferon genes (STING) as a critical mediator of type I interferon production by CD4+ T cells during blood-stage Plasmodium falciparum infection. The activation of STING in CD4+ T cells by cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) stimulated IFNβ gene transcription, which promoted development of IL-10– and IFN-γ–coproducing CD4+ T (type I regulatory [Tr1]) cells. The critical role for type I IFN signaling for Tr1 cell development was confirmed in vivo using a preclinical malaria model. CD4+ T cell sensitivity to STING phosphorylation was increased in healthy volunteers following P. falciparum infection, particularly in Tr1 cells. These findings identified STING expressed by CD4+ T cells as an important mediator of type I IFN production and Tr1 cell development and activation during malaria.

Introduction

Malaria is a devastating human disease of global importance. It not only caused an estimated 247 million cases and 619,000 deaths in 2021, but also promoted poverty by imposing health care and socioeconomic costs on communities in malaria-endemic areas (1). Plasmodium falciparum is responsible for most malaria cases, and despite decades of effort, there is still no licensed vaccine that meets the WHO goal of 75% efficacy against clinical disease (2). Many factors contribute to this failure, including the presence of polymorphic or strain-restricted antigens and suboptimal vaccine formulations and dosing schedules as well as imprinted antiparasitic immune responses that impede rather than enhance vaccine-induced immunity (3–5). In regard to the latter, mounting evidence supports the emergence of potent immune regulatory mechanisms to protect tissues against inflammation following P. falciparum infection (3, 6, 7).

The production of the antiinflammatory cytokine IL-10 and expression of coinhibitory receptors by parasite-specific CD4+ T cells are important components of the immune regulatory networks that arise during malaria (8–10). In fact, IL-10– and IFN-γ–coproducing CD4+ T (type I regulatory [Tr1]) cells comprise a substantial fraction of cells responding to parasite antigen stimulation of immune cells from African children living in malaria-endemic areas (11–14). Evidence from both preclinical models (15–17) and controlled human malaria infection (CHMI) studies (3) indicates that type I IFNs are important drivers of Tr1 cell development during malaria. Type I IFNs play diverse roles in host immune responses during infections and cancer (18, 19). In a preclinical malaria model, type I IFNs suppressed the development of antiparasitic T follicular helper (Tfh) cell responses, thereby limiting parasite-specific antibody production (17). Furthermore, we previously showed that type I IFNs act on dendritic cells to suppress the development of Th1 cells while promoting IL10 gene transcription in a model of experimental malaria (20). We also demonstrated that in volunteers infected with blood-stage P. falciparum, type I IFNs suppressed antigen–specific IFN-γ production while promoting parasite–specific IL-10 production (3). Although we identified CD4+ T cells along with many other immune cell populations as important sources of type I IFNs, we do not know the mechanism of type I IFN induction during malaria. It is also unknown whether CD4+ T cell type I IFN production plays any role in the development of antiparasitic immune responses during malaria, and if so, the identity of relevant cellular and molecular pathways that mediate type I IFN-dependent Tr1 cell development. This information is important if we wish to manipulate Tr1 cell development and/or activity to improve antiparasitic immunity in response to vaccine or drug treatments.
Here, we identified increased expression of TMEM173 (encoding stimulator of interferon genes [STING]) by Tr1 cells, relative to other CD4+ T cell subsets, in volunteers infected with blood-stage \textit{P. falciparum}. Furthermore, we uncovered a role for STING in CD4+ T cell type I IFN production that promoted the development and activation of Tr1 cells using primary human cells. These results were verified in vivo using a preclinical malaria model in mice. Together, our findings identify a critical cell-signaling axis in CD4+ T cells that drives the development and activation of Tr1 cells during malaria, thus providing a potential means for manipulating this key CD4+ T cell subset to improve antiparasitic immunity in the context of either vaccination or drug treatment.

**Results**

\textbf{STING expression by Tr1 cells from volunteers infected with blood-stage \textit{P. falciparum}.} We recently described a transcriptional signature for human Tr1 cells, defined by IL-10 and IFN-γ coproduction, during CHMI studies that distinguished them from IFN-γ-producing CD4+ T (Th1) cells (21). Further interrogation of this data set (Figure 1A) revealed that \textit{TMEM173} (ENSG00000184854; encoding STING) was upregulated by Tr1 cells, compared with Th1 cells and other CD4+ T cells (Figure 1B). Pattern-recognition receptors are emerging as important mediators of costimulatory pathways in T cells, and STING was recently shown to drive T cell type I IFN production in these cells (22, 23). Thus, given the key immune regulatory roles for type I IFNs previously reported in malaria and, in particular, their role in promoting the transition of Th1 cells to Tr1 cells (3), we examined the role of CD4+ T cell STING on the development and activation of Tr1 cells. We first confirmed increased \textit{TMEM173} expression in Tr1 cells in validation experiments (Figure 1C). Next, we employed pathway analysis of the Tr1 cell transcriptomic data to identify molecules that were predicted to interact with IL-10 either directly (direct physical contact) or indirectly (no physical contact, but causes a change in expression). We observed that IL-10 was predicted to indirectly interact with STING as well as interferon regulatory factor 3 (IRF3), a transcription factor downstream of STING activation and a key driver of \textit{IFNBI} gene transcription (24) (Figure 1D). Thus, STING was more highly expressed in Tr1 cells compared with other CD4+ T cell subsets and predicted to be associated with IL-10 and type I IFN production by these cells.

**Modulation of CD4+ T cell STING activation with CRISPR/Cas9 gene editing.** To investigate the role of STING in human CD4+ T cells, we employed CRISPR/Cas9 gene editing of \textit{TMEM173}. We used a previously reported protocol (25, 26) to optimize editing STING expression in primary CD4+ T cells isolated from peripheral blood of healthy volunteers (Supplemental Figure 1, A and B; supplemental material available online with this article; https://doi.org/10.1172/JCI169417DS1). CD4+ T cells were cultured for 3 days with anti-CD3e and anti-CD28 mAbs in the presence of recombinant IL-2 (Figure 2A) before being edited with a guide RNA (gRNA) targeting the \textit{TMEM173} gene (Figure 2B). Following a further 3 days of cell culture under the same conditions, approximately 73% of cells had excisions in exon 4 of the \textit{TMEM173} gene (Supplemental Figure 1, C and D) and reduced \textit{TMEM173} mRNA accumulation (Figure 2C) and STING protein levels (Figure 2D). We confirmed the loss of STING by showing stimulation with the STING agonist cyclic guanosine monophosphate-adenosine monophosphate (cGAMP), resulting in negligible detection of phosphorylated STING (p-STING) (Figure 2E). Thus, we were able to modify \textit{TMEM173} using CRISPR/Cas9 gene editing, resulting in CD4+ T cells that were unable to respond to stimulation with cGAMP.

**CD4+ T cell STING is required for Tr1 cell development.** To identify Tr1 cells without the need for stimulation with strong mitogens such as phorbol myristate acetate (PMA) to detect IL-10 and IFN-γ, we used LAG3 and CD49b, which have previously been shown to be highly expressed by Tr1 cells (27, 28). Tr1 cells identified by LAG3 and CD49b coexpression peaked at day 4 after stimulation of CD4+ T cells with anti-CD3e and anti-CD28 mAbs plus IL-2, and consistent with previous studies (27, 29), LAG3 and CD49b coexpressing cells produced the highest amounts of IL-10 and IFN-γ as well as their transcripts, although IL-10 production peaked 24 hours after stimulation (Supplemental Figure 2). Thus, detection of LAG3 and CD49b coexpression on CD4+ T cells in culture was more reliable than IL-10 production over time (Supplemental Figure 2). However, this latter observation indicates that some caution must be used when assessing Tr1 cells with the former cell-surface markers. Nevertheless, the development of LAG3-CD49b+ Tr1 cells was enhanced by cGAMP (Figure 3A), while there was a decrease in the frequency of other CD4+ T cell subsets, although additional markers for chemokine receptors and transcription factors will be needed to identify these subsets (Supplemental Figure 3, A–C). Regardless, these results show that cGAMP activation of STING promoted Tr1 cell development and that CRISPR/Cas9 gene editing of \textit{TMEM173} in human CD4+ T cells limited this process (Figure 3A). To determine whether Tr1 cells were the main CD4+ T cell subset responding to cGAMP, we examined STING phosphorylation following cGAMP stimulation of activated CD4+ T cells. Indeed, we observed the highest frequency of p-STING+ cells among LAG3-CD49b+ CD4+ T cells (Figure 3B). Stimulation of CD4+ T cells with cGAMP also increased STING-dependent transcription of IL10, IFNG, and IFNBI, but following \textit{TMEM173} gene editing, this was abrogated (Figure 3, C–E). Notably, cGAMP stimulation resulted in no marked increase to the transcription of other type I IFN family members (Supplemental Figure 3D), suggesting selective induction of IFNBI among the type I IFN family of genes in CD4+ T cells.
following STING activation. We attempted to measure IL-10 protein in cell-culture supernatants, but levels were around or below levels of detection. Nevertheless, these results show that CD4+ T cell STING promotes Tr1 cell development and that its activation in these cells drives IL10, IFNG, and IFNB1 transcription.

**STING-dependent IFN-β1 production by CD4+ T cells drives Tr1 cell development.** Type I IFNs not only have potent antiviral activities, but also modulate CD4+ T cell responses during experimental and clinical malaria, including suppressing Th1 and Th2 cell responses (3,15,17,20). Given the strong STING-dependent induction of IFNB1 by Tr1 cells, we next examined the requirement of type I IFN production for Tr1 cell activation or development (Figure 4A). Following CD4+ T cell activation, as above, we found that STING-dependent expansion of Tr1 cells was abrogated by blocking type I IFN signaling with an antibody directed against the type I IFN receptor (IFNR) (Figure 4B). We also observed reduced IL10 and IFNG transcription when type I IFN signaling was blocked (Figure 4B) as well as diminished IFNB1 induction following IFNR blockade (Figure 4B). To directly link CD4+ T cell-autologous STING-dependent IFN-β1 production with Tr1 cell activation and
The results show that STING-dependent IFN-\(\beta\) production by CD4\(^+\) T cells promotes Tr1 cell development and activation. CD4\(^+\) T cell STING is required for optimal IFN-\(\gamma\) and IL-10 production in experimental malaria. To extend the above studies to an in vivo setting, we used an experimental model of severe malaria development, we tested to determine whether Tr1 cell development from STING-deficient CD4\(^+\) T cells could be rescued by exogenous IFN-\(\beta\) (Figure 4G), and indeed this was the case (Figure 4D). We also found that supplementation of CD4\(^+\) T cells with IFN-\(\beta\) alone induced IL10 and IFNG transcription (Figure 4D). Together, these results show that STING-dependent IFN-\(\beta\)1 production by CD4\(^+\) T cells promotes Tr1 cell development and activation.

**Figure 3.** CD4\(^+\) T cell STING activation promotes Tr1 cell development.

Human CD4\(^+\) T cells were cultured and subjected to CRISPR/Cas9 TMEM173 gene editing as shown in Figure 2. (A) Gating strategy used to assess changes in human CD4\(^+\) T cells. Cells were gated on single cells, live cells, and conventional CD4\(^+\) T cells (FoxP3\(^-\)) before further analysis. Representative plots and enumeration showing the frequency of LAG3\(^-\)CD49b\(^+\) CD4\(^+\) T cells following CRISPR/Cas9-mediated modification of TMEM173 expression. Lines connect paired samples, and box shows extent of lower and upper quartiles plus median, while whiskers indicate minimum and maximum data points. (B) Representative histograms and enumeration showing the frequencies of p-STING–positive LAG3\(^-\)CD49b\(^+\), LAG3\(^-\)CD49b\(^-\), LAG3 \(^+\)CD49b\(^+\), and LAG3 \(^+\)CD49b\(^-\) CD4\(^+\) T cell subsets. Box shows the extent of lower and upper quartiles plus median, while whiskers indicate minimum and maximum data points. (C–E) Expression of IL10, IFNG, and IFNB1 in the control and TMEM173-modified cells with and without cGAMP activation was measured by qPCR. Lines connect paired samples, and box shows the extent of lower and upper quartiles plus median, while whiskers indicate minimum and maximum data points. \(n=8\) (A, C–E); \(n=5\) (B). Repeated measures 2-way ANOVA with Šídák’s multiple-comparisons test. * \(P < 0.05\); *** \(P < 0.001\); **** \(P < 0.0001\).
caused by infection of C57BL/6 mice with *P. berghei* ANKA (*PbA*). We employed *PbTII* mice (30, 31), a TCR transgenic mouse line that produces CD4+ T cells specific for I-Aβ-restricted *PbA* heat shock protein 90 expressed by all rodent and human *Plasmodium* species, and crossed these with *Tmem173*-deficient mice (32, 33) to generate STING-deficient *PbTII* cells (*PbTIIΔSting*). WT control *PbTII* cells were generated by crossing *PbTII* TCR transgenic mice with congenic (CD45.1) C57BL/6 mice to produce mice expressing both cd45.1 and cd45.2 alleles (*PbTIIWT*). We then isolated *PbTIIΔSting* and *PbTIIWT* cells from these animals to test the need for CD4+ T cell STING for Tr1 cell development in vivo. We transferred these cells at an equal mix (10⁶ total) into congenic (CD45.1) C57BL/6 recipient mice the day before *PbA* infection (Figure 5A). We then measured cell frequencies and cytokine production at day 4 post infection (p.i.) in the spleen, when Th1 cell responses peak in this tissue in this model (Supplemental Figure 4), and found a decrease in the proportion of splenic *PbTIIΔSting* cells producing IL-10 and an increase in those producing IFN-γ relative to control *PbTIIWT* cells (Figure 5B and Supplemental Figure 5, A and B). Furthermore, there was a decrease in the proportion of IL-10+IFN-γ+ *PbTIIΔSting* Tr1 cells, compared with control *PbTIIWT* cells (Figure 5C). A decreased frequency of *PbTIIΔSting* cells producing granzyme B (GzmB) and...
perforin relative to PbTII WT cells was also observed (Supplemental Figure 6, A–C). The expression of these cytotoxic molecules has previously been associated with both mouse and human Tr1 cells (34, 35). However, differences in Tr1 cells defined by LAG3 and CD49b expression were less consistent between PbTII ΔSting and PbTII WT cells (Figure 5D). It should be noted that the frequency of Tr1 cells defined by LAG3 and CD49b coexpression was lower than when these cells were identified by IFN-γ and IL-10 coexpression (Figure 5, B and C), indicating that the former marker set may not capture all Tr1 cells. Regardless, this result suggests that alternative type I IFN cellular sources (not adoptively transferred PbTII ΔSting cells) were driving expression of LAG3 and CD49b, but not the changes in cytokine, GzmB, or perforin production by CD4+ T cells in vivo. Hence, these results indicate that CD4+ T cell STING promotes IL-10 production while suppressing IFN-γ production in a cell-intrinsic manner in vivo in experimental malaria.

Figure 5. CD4+ T cell STING is required for Tr1 cell development in experimental malaria. (A) 5 × 10^5 CD45.2+ PbTII ΔSting and 5 × 10^5 CD45.1+ PbTII WT cells were transferred into the Ptpcrta (CD45.1) recipient mice at day –1. The mice were infected with P. berghei ANKA (PbA) on day 0 and were assessed on day 4. (B) Representative histograms and enumeration showing the IL-10– and IFN-γ–producing PbTII WT and PbTII ΔSting cells. (C and D) Representative plots and enumeration showing the frequencies of IL-10+IFN-γ+ and LAG3+CD49b+ CD4+ T cells, respectively. Data in each plot were pooled from 3 independent experiments. Lines connect paired samples, and box shows extent of lower and upper quartiles plus median, while whiskers indicate minimum and maximum data points. n = 24. Two-tailed paired t test. ***P < 0.001; ****P < 0.0001.
Type I IFN signaling in CD4+ T cells drives Tr1 cell development in experimental malaria. We showed that STING-dependent IFN-β production by CD4+ T cells drives human Tr1 cell development and activation in vitro (Figure 4). To determine whether cell-intrinsic type I IFN signaling was required for Tr1 cell development and activation in vivo, we again employed the above model of experimental malaria. However, instead of using PbTII<sup>Sting</sup> cells, we crossed PbTII mice with Ifnar-deficient mice (36, 37) to generate Ifnar-deficient PbTII cells (PbTII<sup>ΔIfnar</sup>) that lacked the ability to receive stimulation by type I IFNs. Following transfer of an equal mix (10⁶ total) of PbTII<sup>ΔIfnar</sup> and PbTII<sup>WT</sup> cells into congenic C57BL/6 recipient mice the day before PbA infection, cell frequencies and cytokine production were measured in the spleen at day 4 p.i. (Figure 6A). We found a decreased proportion of splenic PbTII<sup>ΔIfnar</sup> cells producing IL-10 or IFN-γ and a decrease in cells producing IFN-γ plus IL-10 as well as LAG3+CD49b+ Tr1 cells relative to control PbTII<sup>WT</sup> cells (Figure 6, B–D). As previously observed, the decrease in PbTII<sup>ΔIfnar</sup> Tr1 cell frequency was also associated...
with a decreased frequency of Tr1 cells producing GzmB and perforin, relative to PbTII WT Tr1 cells (Supplemental Figure 7). Hence, these results show that CD4+ T cell-intrinsic type I IFN signaling is required for optimal IL-10 and IFN-γ production as well as Tr1 cell development in vivo in experimental malaria. Furthermore, the results suggest that type I IFN signaling plays distinct roles in CD4+ T cell IFN-γ production, whereby it is needed for induction of IFN-γ production, but also promotes the STING/IL-10 axis, which in turn suppresses IFN-γ production by Th1 cells.

**Tr1 cells from humans infected with *P. falciparum* are more sensitive to STING activation.** Our results above indicate that STING-dependent IFN-β1 production by human CD4+ T cells drives Tr1 cell development in vitro and a similar STING-dependent pathway promotes Tr1 cell development in vivo in experimental malaria. Therefore, we hypothesized that CD4+ T cell STING would be more readily activated in parasite-specific CD4+ T cells from humans infected with *P. falciparum*. To test this, we examined peripheral blood CD4+ T cells from volunteers participating in CHMI studies with *P. falciparum* prior to infection and at day 15 p.i. (7 days after start of drug treatment), as we previously showed this was when Tr1 cell responses peaked (3). We first assessed p-STING in CD4+ T cell subsets following stimulation of PBMCs with cGAMP for 1.5 hours, as previously described (38), to evaluate ex vivo sensitivity to STING activation (Figure 7A and Supplemental Figure 8A). The frequency of cells containing p-STING was heterogeneous among volunteers, but peaked in Tr1 cells in most volunteers at day 15 p.i. (Supplemental Figure 8B). At this time, the frequency of Tr1 cells expressing p-STING was greater than in other CD4+ T cell subsets examined (Figure 7B). We next determined whether parasite-specific CD4+ T cells were more sensitive to STING-mediated development into Tr1 cells. PBMCs collected from CHMI volunteers 15 days p.i. were cultured for 18 hours with uninfected red blood cells (uRBCs) and *P. falciparum*-parasitized red blood cells (pRBCs) with or without cGAMP (Figure 7C). PBMCs were used, rather than purified CD4+ T cells, so that APCs were available for parasite antigen presentation. However, the use of PBMCs meant that the ability of Tr1 cells to produce IL-10 and express coinhibitory receptors makes them important for protecting tissues from inflammation (39, 40). However, their immunosuppressive functions may also dampen antiparasitic immunity, thereby impeding the development of natural or vaccine- or drug-mediated protection against disease (12, 41, 42). Previous studies have shown that IL-27 drives the balance between Th1 and Tr1 cell development in mice with experimental malaria (43–46) and involves the transcription factors cMaf (47) and Blimp-1 (42). Our findings identify STING expression by CD4+ T cells as another important molecule in Tr1 cell development. Of note, we recently reported that IL-27 had a limited effect on IL-10 production by human CD4+ T cells and instead played an important role in promoting coinhibitory receptor expression by specific CD4+ T cell subsets (21). Thus, it is likely that, although type I IFNs and IL-27 both affect Tr1 cell development and functions, their roles are distinct.

**Discussion**

In this study, we show STING is expressed by human Tr1 cells following *P. falciparum* infection. Furthermore, activation of STING by cGAMP can drive CD4+ T cell IFN-β1 production that promotes autologous Tr1 cell expansion and/or maintenance as well as increased IL-10 and IFN-γ production following activation.

Tr1 cells have emerged as an important CD4+ T cell subset in numerous clinical contexts (39, 40). In malaria, Tr1 cells develop in healthy volunteers infected with *P. falciparum* soon after treatment with antiparasitic drugs (3) and were observed in African children with malaria (11–14). The ability of Tr1 cells to produce IL-10 and express coinhibitory receptors makes them important for protecting tissues from inflammation (39, 40). However, their immunosuppressive functions may also dampen antiparasitic immunity, thereby impeding the development of natural or vaccine- or drug-mediated protection against disease (12, 41, 42). Previous studies have shown that IL-27 drives the balance between Th1 and Tr1 cell development in mice with experimental malaria (43–46) and involves the transcription factors cMaf (47) and Blimp-1 (42). Our findings identify STING expression by CD4+ T cells as another important molecule in Tr1 cell development. Of note, we recently reported that IL-27 had a limited effect on IL-10 production by human CD4+ T cells and instead played an important role in promoting coinhibitory receptor expression by specific CD4+ T cell subsets (21). Thus, it is likely that, although type I IFNs and IL-27 both affect Tr1 cell development and functions, their roles are distinct.

We identified cGAMP-mediated activation of STING as critical for CD4+ T cell type I IFN production. Furthermore, we showed this promoted an autologous regulatory loop that promoted Tr1 cell development and expansion. Of note, we only detected IFNβ mRNA in human CD4+ T cells following activation with cGAMP, and no other members of the type I IFN cytokine family were examined. Recent studies have shown that in mice, cGAMP can be produced and secreted by cells, then taken up by surrounding cells via the volume-regulated anion channel LRRC8C expressed by T cells to activate STING (48, 49). Hence, one possible mechanism for STING activation in CD4+ T cells is via phagocytic cells capturing pRBCs and detecting parasite DNA, as previously described (50, 51), then secreting cGAMP that is taken up by CD4+ T cells to activate STING and drive Tr1 cell development during malaria.
Figure 7. Tr1 cells from humans infected with *P. falciparum* are more sensitive to STING activation. (A) PBMCs were isolated from volunteers participating in a CHMI study with *P. falciparum* at day 0 and 15 p.i. and stimulated with or without cGAMP for 1.5 hours before analysis. (B) Representative histogram and enumeration showing the expression of p-STING in different Th cell subsets on days 0 and 15 p.i. (C) PBMCs were stimulated with uRBCs or pRBCs for 18 hours with or without cGAMP before analysis of CD4+ T subset frequencies. (D) Tr1 (LAG3+CD49b+) cell frequencies as a percentage of CD4+ T cells are shown. (E) PBMCs were stimulated with uRBCs or pRBCs for 72 hours and stimulated with cGAMP 18 hours before analysis. (F) Frequency of p-STING-CD4+ T cells in the presence of pRBCs with or without cGAMP at days 0 and 15 p.i. (G) Expression of p-STING in different CD4+ T cell subsets in the presence of pRBCs and cGAMP at days 0 and 15 p.i. (H) IL-10 and IFN-γ produced in the cell-culture supernatant in the presence of pRBCs with or without cGAMP at days 0 and 15 p.i. Lines connect paired samples, and box shows extent of lower and upper quartiles plus median, while whiskers indicate minimum and maximum data points. (B, D, F, G and H) n = 8. Repeated measures 2-way ANOVA with Šidák’s multiple-comparisons test. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
In addition to their key roles in innate immune cells, pattern-recognition receptors are being increasingly recognized as playing important roles in the activation and fate of T cells (22). Previous studies have shown that STING activation in CD4+ T cells can induce apoptosis (52, 53) or suppress proliferation (54). The latter role for STING is mediated via the inhibition of the metabolic checkpoint kinase, mechanistic target of rapamycin (mTOR), while simultaneously stimulating type I IFN production (23). Although we know type I IFNs induce IL-10 production (55, 56), our knowledge about the cellular and molecular mechanisms responsible is incomplete. Our findings support a model whereby CD4+ T cell IFN-β production in response to STING activation by cGAMP stimulates IL-10 production as well as Tr1 cell development. However, although we identify an important immune regulatory role for STING-mediated, cell-autologous IFN-β1 production, we did not identify CD4+ T cell IFN-γ production in response to STING activation by cGAMP. STING-dependent Tr1 cell development could be rescued by addition of recombinant IFN-β1 to STING-deficient human CD4+ T cells, indicating that type I IFNs from different cell sources could drive CD4+ T cell activation and differentiation pathways. Most cells are capable of producing type I IFNs (18, 19, 50, 51), and we have previously reported that multiple immune cell populations from volunteers participating in CHMI studies are able to produce these cytokines (3).

There are several potential limitations in our study, including a strict definition for Tr1 cells in malaria. We recently reported that Tr1 cells that emerge following P. falciparum infection represent a heterogeneous cell population, based on the expression of co-inhibitory receptors (21). Furthermore, although we identified CD4+ T cells as important cellular sources of type I IFNs during malaria for driving Tr1 cell development, we did not evaluate the contributions of other cellular sources to this process or the relationship of this cytokine signaling pathway to other immune regulatory pathways in malaria. We also didn’t identify CD4+ T cell STING agonists active during malaria or their cellular source. Finally, the effects of CD4+ T cell STING activation on preexisting Th1 and Tr1 cells from individuals living in malaria-endemic areas were not evaluated.

In summary, we have uncovered a Tr1 cell–development pathway that can be targeted in mice and humans during malaria to alter the balance between parasite-specific Th1 and Tr1 cells. These findings have potential applications in strategies designed to improve vaccine efficacy and/or improve antiparasitic responses following drug treatment, thereby addressing a major bottleneck in efforts to eliminate malaria.

Methods

Human primary cells. PBMCs were isolated using Ficoll-Hypaque (GE Healthcare Bio-Sciences AB), according to the manufacturer’s instructions. PBMCs were suspended in freezing media (90% [v/v] FBS; Gibco/Thermo Fischer Scientific) and 10% (v/v) DMSO (Sigma-Aldrich) and stored at -80°C. PBMCs were thawed and washed with RPMI 1640 media (Life Technologies) and rested in complete media (10% [v/v] FCS, 100 U/ml penicillin, 100 μg/ml streptomycin [penicillin-streptomycin], 1× GlutaMAX, 1× nonessential amino acids, 1 mM sodium pyruvate, 5 mM HEPES [Gibco, Thermo Fisher Scientific] and 0.05 mM 2-mercaptoethanol [Sigma-Aldrich]) in RPMI 1640 containing L-glutamine (Gibco, Thermo Fisher Scientific) for 40 minutes before any further manipulation. Human CD4+ T cells were negatively selected from PBMCs using an EasySep Human CD4+ T Cell Enrichment Kit, according to the manufacturer’s protocol (STEMCELL Technologies).

Nucleofection. Plates (48- or 96-well, flat bottom) were coated with 10 μg/ml αCD3 γ mAbs (BioLegend) and incubated at 37°C for 5 hours, then stored at 4°C overnight. Human CD4+ T cells were stimulated with plate-bound αCD3 γ mAbs and 5 μg/ml soluble αCD28 mAbs (BioLegend) plus 200 U/ml IL-2 (Milenyi Biotec) for 3 days. 225 μl P3 buffer (Amaza P3 Primary Cell 96-well Nucleofector Kit, Lonza) and 50 μl of supplement (Lonza) were mixed to make 275 μl nucleofection buffer. CD4+ T cells were then washed with PBS and suspended in P3 buffer (Lonza) to achieve a final concentration of 5×10^6 to 1×10^7 cells per 20 μl. 2.4 μl CRISPR gRNA (gRNA, Lonza; Supplemental Table 1) (100 μM) and 2 μl Cas9-NLS (80 μM) (a gift from Chris Jeas, QB3 MacroLab, University of California, Berkeley, California, USA) were mixed and incubated for 40 minutes at 37°C. After incubation, 4.4 μl gRNA-Cas9 complex was added to a 20 μl cell suspension in P3 buffer, transferred into a Nucleoette (Lonza), and placed on an Amaza Nucleofector and 96-well Shuttle (Lonza) with the program EH115. After electroporation, cells were rested in warm media for 20 minutes at 37°C and stimulated with 25 μl/ml Immunocult (STEMCELL Technologies) and 200 U/ml IL-2 for another 3 days.

Mice. C57BL/6/J (WT) mice were purchased from the Walter and Eliza Hall Institute (Melbourne, Australia). B6.Sting+/- mice (33) were provided by Rachel Kuns (QIMR Berghofer Medical Research Institute). Transgenic PbTII mice (30, 31) were crossed to B6.Ptprca (CD45.1+) mice to generate PbTII × B6.Cd45.1 (PbTII\textsuperscript{WT}; CD45.1\textsuperscript{CD45.2}). B6.Sting+/- mice were crossed with PbTII mice to generate Sting-deficient PbTII mice (PbTII\textsuperscript{mice}; CD45.1\textsuperscript{CD45.2}). PbTII mice were also crossed to B6.ILnar+/- mice to generate ILnar-deficient PbTII mice (PbTII\textsuperscript{mice}; CD45.1\textsuperscript{CD45.2}). All mice were housed under pathogen-free conditions at the QIMR Berghofer Medical Research Institute Animal Facility.

Plasmodium berghei ANKA infections were established from parasites passaged in C57BL/6J mice. Transgenic P. berghei ANKA (231c11) parasites (200 μl, in-house laboratory stock, frozen at ~80°C) expressing luciferase and GFP (57) were thawed at room temperature (RT) and injected via the intraperitoneal route into a passage mouse. Three days p.i., 1 drop of blood was collected into 250 μl RPMI/PS with 1 IU/ml heparin from passage mice. Then, 50 μl of this blood suspension was stained with 10 μg/ml Hoechst 33342 (Sigma Aldrich) and 5 μM SYTO 84 (Sigma Aldrich) in RPMI/PS for 22 minutes at RT. Next, 300 μl of RPMI/PS was added, and each sample was acquired on a BD LSRFortessa (BD Biosciences). The pRBCs were identified as Hoechst 33342 SYTO 84+. The passage mouse was sacrificed at greater than 1% pRBCs on day 3 p.i. Blood was collected from the passage mouse by cardiac puncture into RPMI/PS containing 1 IU/ml heparin and centrifuged at 290g for 7 minutes at RT. RBCs were counted on a hemocyt-
trometer (Pacific Laboratory Products). A parasite inoculum containing 5 × 10^6 pRBCs per ml was prepared, and mice were injected with 200 μl of the inoculum (1×10^6 pRBCs) intravenously through the lateral tail vein. Blood parasitemia was measured as described above, while parasite biomass was calculated by measuring luciferase transgenic parasite cells in live mice, as previously performed (58).

**Preparation of splenic single-cell suspension.** Mouse spleens were collected and placed in 1% (v/v) FCS in PBS (1% FCS/PBS). Spleens were then mechanically processed through a 100 μm EASYstrainer Cell Strainer (Greiner Bio-One) using the back of a 5 ml syringe plunger (Terumo Medical). Cells were resuspended in 1% FCS/PBS and centrifuged at 350g before being lysed with 1 ml Red Blood Cell Lysing Buffer Hybrid-Max (Sigma Aldrich) for 5 minutes at RT. Cells were then washed with 10 ml of 1% FCS/PBS, resuspended in 5 ml 1% FCS/PBS, and stored at 4°C until required.

**Cotransfer of PbTII cells into recipient mice.** Splenic CD4+ T cells were isolated by MACS using the mouse CD4+ T Cell Isolation Kit (Miltenyi Biotec) according to the manufacturer’s instructions, and 100 μl of a single cell suspension was stained with 1 μg/ml CD4 BV395, TCR-β BV737, CD45.1 FITC, and CD45.2 BV711 (Supplemental Table 1) to make a final volume of up to 10 ml. Then PbTII cells were mixed with PbTII^WT cells at a 1:1 ratio and diluted to 5 × 10^6 cells/ml in RPMI/PS. A 200 μl cell suspension (containing 10^6 cells) was injected intravenously into B6. Ptpcr (CD45.1^+^) recipient mice.

**Flow cytometry.** Human cell/flow cytometry staining was performed in Falcon 96-Well Clear Round Bottom Tissue Culture-Treated Cell Culture Microplates (Corning Inc.). Cells were washed and incubated with LIVE/DEAD Fixable Blue (Life Technologies), monocyte blocker (Invitrogen), and Fc receptor (FcR) True Block (Invitrogen); then washed and incubated with fluorescently conjugated surface-staining antibodies (Supplemental Table 1) for 30 minutes at 37°C. Cells were washed and fixed with fluorescently conjugated surface-staining antibodies (Supplemental Table 1) to check cell purity (>90%). Then PbTIIflox or PbTIIflox^WT cells were mixed with PbTIIflox^WT cells at 1:1 ratio and diluted to 5 × 10^6 cells/ml in RPMI/PS. A 200 μl cell suspension (containing 10^6 cells) was injected intravenously into B6.Ptpcr (CD45.1^+^) recipient mice.

**Surface and intracellular staining.** Mouse prestained cells or spleen cells were washed once and incubated with TrueStain FcR (BioLegend), True-Stain Monocyte Blocker (BioLegend), and LIVE/DEAD Fixable Aqua Dead Cell Stain (Life Technologies) for 15 minutes at 37°C. After incubation, cells were stained and fixed following the same procedures as used for the human sample processing described above.

**PCR for detection of genetic modifications.** DNA from CRISPR-edited and control cells was extracted by QuickExtract DNA Extraction Solution, according to the manufacturer’s instructions (Lucigen). The DNA was amplified with TMEM173 primers (Supplemental Table 1), and 2 μl of genomic DNA (1:3 diluted), 5 μl 5x PCR buffer, 2 μl 25 mM MgCl2, 0.5 μl 10 mM dNTP, 0.5 μl 10 μM forward primer, 0.5 μl 10 μM reverse primer, and 0.125 U/μl GoTag DNA Polymerase (Promega) were mixed to make a 25 μl PCR reaction mix (Supplemental Table 1). PCR was then performed in a T100 Thermal Cycler (Bio-Rad) using conditions outlined in Table 1.

**T7 endonuclease 1 mismatch assay.** After PCR amplification, 10 μl PCR products were incubated with 1.5 μl 10 NEBuffer (New England Biolabs) and 1.5 μl nuclease-free water with the thermal cycler setting at 10 minutes for 95°C, then 95°C–85°C (ramp rate of -2°C/second), and finally 85°C–25°C (ramp rate of –0.3°C/second). Then 13 μl PCR heteroduplexes were digested by 2 μl of 1 U/μl T7 Endonuclease 1 (New England Biolabs) at 37°C for 60 minutes. The digestion of CRISPR-edited DNA was visualized by running on a 5% (w/v) agarose gel.

**Big dye sequencing.** PCR products (1–2 ng per 100 base pairs) were treated with ExoSAP-IT PCR Product Cleanup Reagent (Life Technologies) at a ratio of 5:2 at 37°C for 4 minutes, then 80°C for 1 minute. The PCR products were mixed with 6 pmol TMEM173 forward primer (Supplemental Table 1) to make a final volume of up to 10 μl. Then the PCR products were submitted to the QIMR DNA-Seq facility for Big Dye sequencing.

**Western blotting.** Cells were lysed with 500 μl RIPA buffer (Cell Signaling Technology) with 1x PMSF (Cell Signaling Technology) and protease inhibitor cocktail (Cell Signaling Technology) per 10^7 cells. According to the manufacturer’s protocol, the protein concentration was measured using a DC Protein Assay Kit II (Bio-Rad). The cell lysate was denatured at 75°C for 10 minutes, and the protein was separated by Bolt 4% to 12% (w/v) Bis-Tris Plus Gels (Life Technologies) and transferred onto a PVDF membrane (Millennium Science). The membrane was blocked with 50 μl Odyssey Blocking Buffer (LI-COR Bioscience) at RT for 1 hour and then incubated with 1/1,000 diluted anti-STING mAbs (Cell Signaling Technology) at 4°C overnight. On the second day, the membrane was washed and incubated with 0.2 μg/ml diluted IRDye 680RD donkey anti-mouse IgG secondary antibody and IRDye 800CW goat anti-rat IgG secondary antibody (LI-COR Bioscience, Supplemental Table 1) at RT for 30 minutes. The signal was detected using the Licor Odyssey CLx (Millennium Science).

**Cytometric bead array.** A human Th1/Th2/Th17 Cytokine Kit (BD Biosciences) was used to measure the production of cytokines per the manufacturer’s instructions. Assays were run on a 4 laser BD LSRFortessa Cell Analyzer (BD Biosciences). Cytometric bead array (CBA) data were analyzed using BD CBA FCAP Array software, version 3.0.

**RNA extraction.** Cells were washed and lysed with 350 μl RLT buffer (QIAGEN). RNA was extracted using the RNeasy Mini Kit (QIA-GEN) according to the manufacturer’s instructions. The concentration of RNA (ng/μl) and sample purity (260/280 ratio) was measured using the NanoDrop 2000 UV-Vis Spectrophotometer (Thermo Fisher Scientific).
IPA. Upstream pathway analysis was performed on each data set was performed using default values and parameters set on way Analysis (IPA) (version 43605602; QIAGEN). Initial interrogation of cules/ gene interactions related to the RNA-Seq data were identified. was used, direct and indirect interactions were selected, and the mole-

<table>
<thead>
<tr>
<th>Year</th>
<th>Cohort</th>
<th>Subject</th>
<th>Age</th>
<th>Sex</th>
<th>Drug, dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>2018</td>
<td>QP17C19</td>
<td>R201</td>
<td>18</td>
<td>Male</td>
<td>Artefenomel, 800 mg/ piperaquine, 960 mg</td>
</tr>
<tr>
<td></td>
<td></td>
<td>R202</td>
<td>29</td>
<td>Male</td>
<td>Artefenomel, 200 mg/ piperaquine, 320 mg</td>
</tr>
<tr>
<td></td>
<td></td>
<td>R203</td>
<td>23</td>
<td>Male</td>
<td>Artefenomel, 200 mg/ piperaquine, 320 mg</td>
</tr>
<tr>
<td></td>
<td></td>
<td>R204</td>
<td>22</td>
<td>Female</td>
<td>Artefenomel, 200 mg/ piperaquine, 320 mg</td>
</tr>
<tr>
<td></td>
<td></td>
<td>R205</td>
<td>23</td>
<td>Male</td>
<td>Artefenomel, 800 mg/ piperaquine, 960 mg</td>
</tr>
<tr>
<td></td>
<td></td>
<td>R206</td>
<td>22</td>
<td>Male</td>
<td>Artefenomel, 800 mg/ piperaquine, 960 mg</td>
</tr>
<tr>
<td></td>
<td></td>
<td>R207</td>
<td>22</td>
<td>Female</td>
<td>Artefenomel, 800 mg/ piperaquine, 960 mg</td>
</tr>
<tr>
<td></td>
<td></td>
<td>R208</td>
<td>21</td>
<td>Female</td>
<td>Artefenomel, 200 mg/ piperaquine, 320 mg</td>
</tr>
</tbody>
</table>

Written, informed consent was received from all participants. Berghofer Human Research Ethics Committee (approval P1479). Values of less than 0.05 were considered significant.

Written, informed consent was received from all participants. Berghofer Human Research Ethics Committee (approval P1479). Values of less than 0.05 were considered significant.

Statistical analysis was performed using GraphPad Prism 6 (GraphPad Software). Analysis of human cellular assays was performed using a 2-tailed, paired t test and 1-way or 2-way ANOVA performed using a 2-tailed, paired t test. P values of less than 0.05 were considered significant.

Study approval. Human studies were undertaken at Q-Pharm Pty. Ltd. (Brisbane, Australia) under the approval of the QIMR Berghofer Human Research Ethics Committee (approval P1479). Written, informed consent was received from all participants.

Address correspondence to: Christian R. Engwerda, QIMR Berghofer Medical Research Institute, 19 Research Institute, 300 Herston Road, Herston, QLD Australia 4006. Phone: 61.7336204281; Email: christian.engwerda@qimrberghofer.edu.au.

4. Nahrendorf W, et al. Inducible mechanisms...
of disease tolerance provide an alternative strategy of acquired immunity to malaria. Elife. 2021;10:e58338.
44. McNab FW, et al. Type I IFN induces IL-10 production in an IL-27-independent manner and blocks responsiveness to IFN-γ for production.

